Clavulanic acid - Opus Genetics
Alternative Names: Clavulanic acid CR - Opus Genetics; Clavulanic acid extended-release (Serdaxin) - Opus Genetics; Clavulanic acid IR - Opus Genetics; RX-10100; Serdaxin; ZoraxelLatest Information Update: 24 Oct 2024
At a glance
- Originator Revaax Pharmaceuticals
- Developer National Institute of Neurological Disorders and Stroke; Rexahn Pharmaceuticals
- Class 2 ring heterocyclic compounds; Antidepressants; Anxiolytics; Azetidines; Carboxylic acids; Erectile dysfunction therapies; Neuroprotectants; Oxazolidinones; Small molecules
- Mechanism of Action Beta lactamase inhibitors; Dopamine release stimulants; Serotonin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Erectile dysfunction; Major depressive disorder
Highest Development Phases
- Discontinued Anxiety disorders; Erectile dysfunction; Major depressive disorder; Neurodegenerative disorders; Parkinson's disease